StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Wednesday. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of NAVB stock opened at $0.00 on Wednesday. Navidea Biopharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.15. The company has a market capitalization of $100,084.00, a price-to-earnings ratio of -0.02 and a beta of 1.47.
Navidea Biopharmaceuticals Company Profile
Further Reading
- Five stocks we like better than Navidea Biopharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to Calculate Options Profits
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.